Drugs & Targets FDA approves Kyprolis with dexamethasone for relapsed or refractory multiple myeloma October 05, 2018Vol.44 No.37
Drugs & Targets FDA authorizes first next-gen sequencing-based test in patients with ALL, MM October 05, 2018Vol.44 No.37
Drugs & Targets FDA approves Libtayo as first and only treatment for advanced CSCC October 05, 2018Vol.44 No.37
Drugs & TargetsFree FDA grants QIDP and Fast Track Designations to Cidara September 28, 2018Vol.44 No.36
Drugs & TargetsFree Blincyto approved In Japan for relapsed or refractory B-cell ALL September 28, 2018Vol.44 No.36
Drugs & Targets European Commission approves Braftovi + Mektovi for advanced BRAF-mutant melanoma September 21, 2018Vol.44 No.35
Drugs & Targets OBI Pharma granted Orphan Drug Designation for treatment of ALL September 21, 2018Vol.44 No.35
